116 related articles for article (PubMed ID: 15555886)
1. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
[TBL] [Abstract][Full Text] [Related]
2. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Steward J; Piercy T; Lever MS; Simpson AJ; Brooks TJ
Int J Antimicrob Agents; 2006 May; 27(5):439-43. PubMed ID: 16621457
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
Russell P; Eley SM; Green M; Stagg AJ; Taylor RR; Nelson M; Beedham RJ; Bell DL; Rogers D; Whittington D; Titball RW
J Antimicrob Chemother; 1998 Feb; 41(2):301-5. PubMed ID: 9533478
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Piercy T; Steward J; Lever MS; Brooks TJ
J Antimicrob Chemother; 2005 Dec; 56(6):1069-73. PubMed ID: 16223941
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Sorgel F; Bassett J; Miller L; Sullivan LJ; Kinzig-Schippers M; Drusano GL
J Infect Dis; 2007 Sep; 196(5):782-7. PubMed ID: 17674322
[TBL] [Abstract][Full Text] [Related]
6. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
[TBL] [Abstract][Full Text] [Related]
7. Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Steward J; Lever MS; Simpson AJ; Sefton AM; Brooks TJ
J Antimicrob Chemother; 2004 Jul; 54(1):95-9. PubMed ID: 15163650
[TBL] [Abstract][Full Text] [Related]
8. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.
Russell P; Eley SM; Bell DL; Manchee RJ; Titball RW
J Antimicrob Chemother; 1996 Apr; 37(4):769-74. PubMed ID: 8722542
[TBL] [Abstract][Full Text] [Related]
9. Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
Steward J; Piercy T; Lever MS; Nelson M; Simpson AJ; Brooks TJ
J Antimicrob Chemother; 2005 Apr; 55(4):523-7. PubMed ID: 15731198
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague.
Lemaître N; Ricard I; Pradel E; Foligné B; Courcol R; Simonet M; Sebbane F
PLoS One; 2012; 7(12):e52503. PubMed ID: 23285069
[TBL] [Abstract][Full Text] [Related]
11. Activation of Heme Oxygenase Expression by Cobalt Protoporphyrin Treatment Prevents Pneumonic Plague Caused by Inhalation of
Willix JL; Stockton JL; Olson RM; Anderson PE; Anderson DM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015027
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Adamovicz JJ; Amemiya K; Fast RL; Miller L; Opal SM; Palardy J; Parejo NA; Sörgel F; Kinzig-Schippers M; Drusano GL
Antimicrob Agents Chemother; 2014 Jun; 58(6):3276-84. PubMed ID: 24687492
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Ryzhko IV; Tsuraeva RI; Anisimov BI; Trishina AV
Antibiot Khimioter; 2009; 54(5-6):37-40. PubMed ID: 20052916
[TBL] [Abstract][Full Text] [Related]
15.
Steenbergen J; Tanaka SK; Miller LL; Halasohoris SA; Hershfield JR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223382
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
[TBL] [Abstract][Full Text] [Related]
17. [A comparative study of fluoroquinolones and 3rd-generation cephalosporins in the prevention and treatment of experimental plague caused by Yersinia pestis strains typical and serologically atypical with respect to F1].
Ryzhko IV; Shcherbaniuk AI; Tsuraeva RI; Samokhodkina ED; Kasatkina IV; Tsetskhladze NS; Pasiukov VV; Roshchina NV
Antibiot Khimioter; 1997; 42(1):12-6. PubMed ID: 9221699
[TBL] [Abstract][Full Text] [Related]
18. [Lack of levofloxacin and moxyfloxacin efficacy in experimental plague of albino mice infected with nalidixic acid resistant pathogen (Nal(r))].
Ryzhko IV; Trishina AV; Verkina LM
Antibiot Khimioter; 2010; 55(11-12):22-4. PubMed ID: 21574421
[TBL] [Abstract][Full Text] [Related]
19. Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice.
Davis KJ; Vogel P; Fritz DL; Steele KE; Pitt ML; Welkos SL; Friedlander AM; Byrne WR
Arch Pathol Lab Med; 1997 Aug; 121(8):865-8. PubMed ID: 9278616
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the effectiveness of antibacterial substances in treating an experimental form of bubonic plague in monkeys].
Romanov VE; Evstigneev VI; Vasil'ev NT; Shabalin BA; Paramonov VE
Antibiot Khimioter; 2001; 46(8):6-8. PubMed ID: 11871319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]